_id
69172a5a3c536f8df2316d9b
Ticker
VRCDF
Name
Verici Dx plc
Exchange
PINK
Address
Avon House, Cardiff, United Kingdom, CF64 2EZ
Country
USA
Sector
Healthcare
Industry
Diagnostics & Research
Currency
USD
Website
https://vericidx.com
Description
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functional binding multicell assay. In addition, the company provides bioinformatics and data science services for exome analysis options; RNA pipeline; multiomic signature discovery, TCR clonotype antigen identification, custom pipeline building, and predictive modeling; and simulation of 100s of drug combinations against multiomic personalized tumor models. It has collaborations with One Lambda Inc. for the commercialization of pre transplant risk assessment (PTRA), a pre-transplant prognosis test for the risk of early acute rejection; The Westmead Institute for Medical Research to determine the factors contributing to graft loss in organ transplants; and FBB Biomed, Inc., which provides research-use-only tests for clinicians seeking insights into neurologic diseases, such as multiple sclerosis and long COVID. Verici Dx plc was incorporated in 2020 and is based in Cardiff, the United Kingdom.
Last Close
0.003
Volume
-
Current Price
0.003
Change
0
Last Updated
2026-01-08T12:26:28.087Z
Image
https://logo.clearbit.com/vericidx.com
Ipo Date
-
Market Cap
4540182
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
1913000
Cost Of Revenue
352000
Gross Profit
1561000
Operating Expenses
4661000
Operating Income
-3100000
Interest Expense
9528
Pretax Income
-3090000
Net Income
-3090000
Eps
-0.012740089039451546
Dividends Per Share
-
Shares Outstanding
1513394127
Income Tax Expense
-
EBITDA
-2800000
Operating Margin
-162.0491374803973
Total Other Income Expense Net
10000
Cash
467000
Short Term Investments
-
Receivables
846000
Inventories
-
Total Current Assets
1749000
Property Plant Equipment
652000
Total Assets
4545000
Payables
971000
Short Term Debt
284253
Long Term Debt
-
Total Liabilities
2063000
Equity
2482000
Bs_currency_symbol
USD
Depreciation
300000
Change In Working Capital
-778000
Cash From Operations
-3716009
Capital Expenditures
4.74
Cash From Investing
-65638
Cash From Financing
-94223
Net Change In Cash
-3588950
Cf_currency_symbol
-
PE
-
PB
0.29316052699435935
ROE
-124.49637389202258
ROA
-67.98679867986799
FCF
-3716013.74
Fcf Percent
-1.9425058755880817
Piotroski FScore
0
Health Score
29
Deep Value Investing Score
5
Defensive Investing Score
6
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
1.5
Growth Investing Score
0.5
Momentum Investing Score
4
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
1913000
Quarters > 0 > income Statement > cost Of Revenue
352000
Quarters > 0 > income Statement > gross Profit
1561000
Quarters > 0 > income Statement > operating Expenses
4661000
Quarters > 0 > income Statement > operating Income
-3100000
Quarters > 0 > income Statement > interest Expense
9528
Quarters > 0 > income Statement > pretax Income
-3090000
Quarters > 0 > income Statement > net Income
-3090000
Quarters > 0 > income Statement > eps
-0.012740089039451546
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
242541476
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-2800000
Quarters > 0 > income Statement > operating Margin
-162.0491374803973
Quarters > 0 > income Statement > total Other Income Expense Net
10000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
467000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
846000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
1749000
Quarters > 0 > balance Sheet > property Plant Equipment
652000
Quarters > 0 > balance Sheet > total Assets
4545000
Quarters > 0 > balance Sheet > payables
971000
Quarters > 0 > balance Sheet > short Term Debt
284253
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
2063000
Quarters > 0 > balance Sheet > equity
2482000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-3090000
Quarters > 0 > cash Flow > depreciation
300000
Quarters > 0 > cash Flow > change In Working Capital
-778000
Quarters > 0 > cash Flow > cash From Operations
-3716009
Quarters > 0 > cash Flow > capital Expenditures
4.74
Quarters > 0 > cash Flow > cash From Investing
-65638
Quarters > 0 > cash Flow > cash From Financing
-94223
Quarters > 0 > cash Flow > net Change In Cash
-3588950
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.012740089039451546
Quarters > 0 > ratios > PB
0.29316052699435935
Quarters > 0 > ratios > ROE
-124.49637389202258
Quarters > 0 > ratios > ROA
-67.98679867986799
Quarters > 0 > ratios > FCF
-3716013.74
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-1.9425058755880817
Quarters > 0 > health Score
29
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
303372
Quarters > 1 > income Statement > gross Profit
-303372
Quarters > 1 > income Statement > operating Expenses
4225888
Quarters > 1 > income Statement > operating Income
-4529260
Quarters > 1 > income Statement > interest Expense
8723
Quarters > 1 > income Statement > pretax Income
-4386782
Quarters > 1 > income Statement > net Income
-4386782
Quarters > 1 > income Statement > eps
-0.01808672921574865
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
242541476
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-4074692
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
142478
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
4061000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
49948
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
4565000
Quarters > 1 > balance Sheet > property Plant Equipment
858000
Quarters > 1 > balance Sheet > total Assets
7492000
Quarters > 1 > balance Sheet > payables
658000
Quarters > 1 > balance Sheet > short Term Debt
182000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
2227000
Quarters > 1 > balance Sheet > equity
5265000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-4386782
Quarters > 1 > cash Flow > depreciation
303372
Quarters > 1 > cash Flow > change In Working Capital
1494754
Quarters > 1 > cash Flow > cash From Operations
-2571199
Quarters > 1 > cash Flow > capital Expenditures
2625
Quarters > 1 > cash Flow > cash From Investing
-93091
Quarters > 1 > cash Flow > cash From Financing
-232502
Quarters > 1 > cash Flow > net Change In Cash
-2959325
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.01808672921574865
Quarters > 1 > ratios > PB
0.13820027122507123
Quarters > 1 > ratios > ROE
-83.31969610636277
Quarters > 1 > ratios > ROA
-58.552883075280306
Quarters > 1 > ratios > FCF
-2573824
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
42
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
3339000
Quarters > 2 > income Statement > cost Of Revenue
389129
Quarters > 2 > income Statement > gross Profit
2949871
Quarters > 2 > income Statement > operating Expenses
4792000
Quarters > 2 > income Statement > operating Income
-1453000
Quarters > 2 > income Statement > interest Expense
12954
Quarters > 2 > income Statement > pretax Income
-1348000
Quarters > 2 > income Statement > net Income
-1348000
Quarters > 2 > income Statement > eps
-0.00605596165914966
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
222590577
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-1065000
Quarters > 2 > income Statement > operating Margin
-43.51602276130578
Quarters > 2 > income Statement > total Other Income Expense Net
105000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
7015000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
1500000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
8949000
Quarters > 2 > balance Sheet > property Plant Equipment
1073000
Quarters > 2 > balance Sheet > total Assets
12106000
Quarters > 2 > balance Sheet > payables
661000
Quarters > 2 > balance Sheet > short Term Debt
184000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
2245000
Quarters > 2 > balance Sheet > equity
9861000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-1348000
Quarters > 2 > cash Flow > depreciation
775702
Quarters > 2 > cash Flow > change In Working Capital
-590000
Quarters > 2 > cash Flow > cash From Operations
-6141650
Quarters > 2 > cash Flow > capital Expenditures
14000
Quarters > 2 > cash Flow > cash From Investing
-189926
Quarters > 2 > cash Flow > cash From Financing
7536000
Quarters > 2 > cash Flow > net Change In Cash
7015000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.00605596165914966
Quarters > 2 > ratios > PB
0.06771845968968665
Quarters > 2 > ratios > ROE
-13.670013183247134
Quarters > 2 > ratios > ROA
-11.134974392863043
Quarters > 2 > ratios > FCF
-6155650
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-1.843560946391135
Quarters > 2 > health Score
33
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
1669500
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
1669500
Quarters > 3 > income Statement > operating Expenses
2396000
Quarters > 3 > income Statement > operating Income
-726500
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-674000
Quarters > 3 > income Statement > net Income
-674000
Quarters > 3 > income Statement > eps
-0.00302798082957483
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
222590577
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-532500
Quarters > 3 > income Statement > operating Margin
-43.51602276130578
Quarters > 3 > income Statement > total Other Income Expense Net
52500
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
7015000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
1500000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
8949000
Quarters > 3 > balance Sheet > property Plant Equipment
1073000
Quarters > 3 > balance Sheet > total Assets
12106000
Quarters > 3 > balance Sheet > payables
661000
Quarters > 3 > balance Sheet > short Term Debt
184000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
2245000
Quarters > 3 > balance Sheet > equity
9861000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-674000
Quarters > 3 > cash Flow > depreciation
194000
Quarters > 3 > cash Flow > change In Working Capital
-295000
Quarters > 3 > cash Flow > cash From Operations
-1588500
Quarters > 3 > cash Flow > capital Expenditures
7000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
3768000
Quarters > 3 > cash Flow > net Change In Cash
-
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.00302798082957483
Quarters > 3 > ratios > PB
0.06771845968968665
Quarters > 3 > ratios > ROE
-6.835006591623567
Quarters > 3 > ratios > ROA
-5.567487196431522
Quarters > 3 > ratios > FCF
-1595500
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-0.955675351901767
Quarters > 3 > health Score
33
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
3339000
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
3339000
Annuals > 0 > income Statement > operating Expenses
9445000
Annuals > 0 > income Statement > operating Income
-6106000
Annuals > 0 > income Statement > interest Expense
22000
Annuals > 0 > income Statement > pretax Income
-5874000
Annuals > 0 > income Statement > net Income
-5874000
Annuals > 0 > income Statement > eps
-0.025248442698921493
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
232648012
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-5151000
Annuals > 0 > income Statement > operating Margin
-182.869122491764
Annuals > 0 > income Statement > total Other Income Expense Net
232000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
4061000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
49948
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
4565000
Annuals > 0 > balance Sheet > property Plant Equipment
858000
Annuals > 0 > balance Sheet > total Assets
7492000
Annuals > 0 > balance Sheet > payables
658000
Annuals > 0 > balance Sheet > short Term Debt
182000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
2227000
Annuals > 0 > balance Sheet > equity
5265000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-5874000
Annuals > 0 > cash Flow > depreciation
701000
Annuals > 0 > cash Flow > change In Working Capital
-650000
Annuals > 0 > cash Flow > cash From Operations
-6020000
Annuals > 0 > cash Flow > capital Expenditures
193000
Annuals > 0 > cash Flow > cash From Investing
61000
Annuals > 0 > cash Flow > cash From Financing
7322000
Annuals > 0 > cash Flow > net Change In Cash
1416000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-0.025248442698921493
Annuals > 0 > ratios > PB
0.1325629698005698
Annuals > 0 > ratios > ROE
-111.56695156695157
Annuals > 0 > ratios > ROA
-78.40363053924186
Annuals > 0 > ratios > FCF
-6213000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-1.8607367475292003
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
1013000
Annuals > 1 > income Statement > cost Of Revenue
1
Annuals > 1 > income Statement > gross Profit
1013000
Annuals > 1 > income Statement > operating Expenses
9880000
Annuals > 1 > income Statement > operating Income
-8867000
Annuals > 1 > income Statement > interest Expense
29000
Annuals > 1 > income Statement > pretax Income
-8734000
Annuals > 1 > income Statement > net Income
-8734000
Annuals > 1 > income Statement > eps
-0.05128017095190857
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
170319245
Annuals > 1 > income Statement > income Tax Expense
5
Annuals > 1 > income Statement > EBITDA
-7876000
Annuals > 1 > income Statement > operating Margin
-875.3208292201382
Annuals > 1 > income Statement > total Other Income Expense Net
133000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
2645000
Annuals > 1 > balance Sheet > short Term Investments
-3735
Annuals > 1 > balance Sheet > receivables
1098446
Annuals > 1 > balance Sheet > inventories
1899
Annuals > 1 > balance Sheet > total Current Assets
3989000
Annuals > 1 > balance Sheet > property Plant Equipment
1363000
Annuals > 1 > balance Sheet > total Assets
7443000
Annuals > 1 > balance Sheet > payables
475000
Annuals > 1 > balance Sheet > short Term Debt
163000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
3885000
Annuals > 1 > balance Sheet > equity
3558000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-8734000
Annuals > 1 > cash Flow > depreciation
829000
Annuals > 1 > cash Flow > change In Working Capital
-824000
Annuals > 1 > cash Flow > cash From Operations
-7160000
Annuals > 1 > cash Flow > capital Expenditures
231000
Annuals > 1 > cash Flow > cash From Investing
-231000
Annuals > 1 > cash Flow > cash From Financing
-27000
Annuals > 1 > cash Flow > net Change In Cash
-7160000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.05128017095190857
Annuals > 1 > ratios > PB
0.1436081323777403
Annuals > 1 > ratios > ROE
-245.47498594716131
Annuals > 1 > ratios > ROA
-117.34515652290742
Annuals > 1 > ratios > FCF
-7391000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-7.296150049358341
Annuals > 1 > health Score
23
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
628371
Annuals > 2 > income Statement > gross Profit
-628371
Annuals > 2 > income Statement > operating Expenses
11455000
Annuals > 2 > income Statement > operating Income
-11455000
Annuals > 2 > income Statement > interest Expense
5000
Annuals > 2 > income Statement > pretax Income
-11407000
Annuals > 2 > income Statement > net Income
-11407000
Annuals > 2 > income Statement > eps
-0.06927282192723659
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
164667754
Annuals > 2 > income Statement > income Tax Expense
53000
Annuals > 2 > income Statement > EBITDA
-10566470
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
48000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
9805000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
177956
Annuals > 2 > balance Sheet > inventories
-2809
Annuals > 2 > balance Sheet > total Current Assets
10325000
Annuals > 2 > balance Sheet > property Plant Equipment
2010000
Annuals > 2 > balance Sheet > total Assets
14305000
Annuals > 2 > balance Sheet > payables
960000
Annuals > 2 > balance Sheet > short Term Debt
156000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
2796000
Annuals > 2 > balance Sheet > equity
11509000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-11407000
Annuals > 2 > cash Flow > depreciation
640000
Annuals > 2 > cash Flow > change In Working Capital
429000
Annuals > 2 > cash Flow > cash From Operations
-10068000
Annuals > 2 > cash Flow > capital Expenditures
1308000
Annuals > 2 > cash Flow > cash From Investing
-1308000
Annuals > 2 > cash Flow > cash From Financing
12674000
Annuals > 2 > cash Flow > net Change In Cash
-535000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.06927282192723659
Annuals > 2 > ratios > PB
0.04292321331132158
Annuals > 2 > ratios > ROE
-99.11373707533235
Annuals > 2 > ratios > ROA
-79.74134917860887
Annuals > 2 > ratios > FCF
-11376000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
430274
Annuals > 3 > income Statement > gross Profit
-430274
Annuals > 3 > income Statement > operating Expenses
8511839
Annuals > 3 > income Statement > operating Income
-8329829
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-8329829
Annuals > 3 > income Statement > net Income
-8329829
Annuals > 3 > income Statement > eps
-0.058765131167876336
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
141747816
Annuals > 3 > income Statement > income Tax Expense
178898
Annuals > 3 > income Statement > EBITDA
-7757200
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
141528
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
10339788
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
249167
Annuals > 3 > balance Sheet > inventories
1284
Annuals > 3 > balance Sheet > total Current Assets
10995635
Annuals > 3 > balance Sheet > property Plant Equipment
785736
Annuals > 3 > balance Sheet > total Assets
13788994
Annuals > 3 > balance Sheet > payables
160000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
1804109
Annuals > 3 > balance Sheet > equity
11984885
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-8329829
Annuals > 3 > cash Flow > depreciation
437756
Annuals > 3 > cash Flow > change In Working Capital
814800
Annuals > 3 > cash Flow > cash From Operations
-6336444
Annuals > 3 > cash Flow > capital Expenditures
965859
Annuals > 3 > cash Flow > cash From Investing
-965859
Annuals > 3 > cash Flow > cash From Financing
-73548
Annuals > 3 > cash Flow > net Change In Cash
-7411299
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.058765131167876336
Annuals > 3 > ratios > PB
0.03548164609005426
Annuals > 3 > ratios > ROE
-69.50278621780684
Annuals > 3 > ratios > ROA
-60.40925828236635
Annuals > 3 > ratios > FCF
-7302303
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.012740089039451546
Valuation > metrics > PB
0.29316052699435935
Valuation > final Score
70
Valuation > verdict
70.7% Undervalued
Profitability > metrics > ROE
-124.49637389202258
Profitability > metrics > ROA
-176.67238421955403
Profitability > metrics > Net Margin
-1.615263983272347
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.8311845286059629
Risk > metrics > Interest Coverage
-325.3568429890848
Risk > final Score
-1253
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.393344608616749
Liquidity > metrics > Quick Ratio
1.393344608616749
Liquidity > final Score
85
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-2017
Prev Risks > 1
-389
Prev Risks > 2
39
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:47:33.076Z
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functional binding multicell assay. In addition, the company provides bioinformatics and data science services for exome analysis options; RNA pipeline; multiomic signature discovery, TCR clonotype antigen identification, custom pipeline building, and predictive modeling; and simulation of 100s of drug combinations against multiomic personalized tumor models. It has collaborations with One Lambda Inc. for the commercialization of pre transplant risk assessment (PTRA), a pre-transplant prognosis test for the risk of early acute rejection; The Westmead Institute for Medical Research to determine the factors contributing to graft loss in organ transplants; and FBB Biomed, Inc., which provides research-use-only tests for clinicians seeking insights into neurologic diseases, such as multiple sclerosis and long COVID. Verici Dx plc was incorporated in 2020 and is based in Cardiff, the United Kingdom.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Verici Dx plc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.